References
- Savarino A, Boelaert JR, Cassone A, Majori G and Cauda R (2003) Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis 3, 722-727 https://doi.org/10.1016/S1473-3099(03)00806-5
- Savarino A, Di Trani L, Donatelli I, Cauda R and Cassone A (2006) New insights into the antiviral effects of chloroquine. Lancet Infect Dis 6, 67-69 https://doi.org/10.1016/S1473-3099(06)70361-9
- Vincent MJ, Bergeron E, Benjannet S et al (2005) Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2, 69 https://doi.org/10.1186/1743-422X-2-69
- Wang M, Cao R, Zhang L et al (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30, 269-271 https://doi.org/10.1038/s41422-020-0282-0
- Yao X, Ye F, Zhang M et al (2020) In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis 71, 732-739 https://doi.org/10.1093/cid/ciaa237
- Gautret P, Lagier JC, Parola P et al (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 56, 105949 https://doi.org/10.1016/j.ijantimicag.2020.105949
- Colson P, Rolain JM and Raoult D (2020) Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents 55, 105923 https://doi.org/10.1016/j.ijantimicag.2020.105923
- Satarker S, Ahuja T, Banerjee M et al (2020) Hydroxychloroquine in COVID-19: Potential mechanism of action against SARS-CoV-2. Curr Pharmacol Rep 6, 203-211 https://doi.org/10.1007/s40495-020-00231-8
- Das S, Bhowmick S, Tiwari S and Sen S (2020) An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19). Clin Drug Investig 40, 591-601 https://doi.org/10.1007/s40261-020-00927-1
- Pillat MM, Kruger A, Guimaraes LMF et al (2020) Insights in chloroquine action: perspectives and implications in Malaria and COVID-19. Cytometry A 97, 872-881 https://doi.org/10.1002/cyto.a.24190
- Boulware DR, Pullen MF, Bangdiwala AS et al (2020) A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med 383, 517-525 https://doi.org/10.1056/NEJMoa2016638
- Chatre C, Roubille F, Vernhet H, Jorgensen C and Pers YM (2018) Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature. Drug Saf 41, 919-931 https://doi.org/10.1007/s40264-018-0689-4
- White NJ (2007) Cardiotoxicity of antimalarial drugs. Lancet Infect Dis 7, 549-558 https://doi.org/10.1016/S1473-3099(07)70187-1
- Min JY and Jang YJ (2012) Macrolide therapy in respiratory viral infections. Mediators Inflamm 2012, 649570
- Tran DH, Sugamata R, Hirose T et al (2019) Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A (H1N1)pdm09 virus infection by interfering with virus internalization process. J Antibiot (Tokyo) 72, 759-768 https://doi.org/10.1038/s41429-019-0204-x
- Scherrmann JM (2020) Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy. AAPS J 22, 86 https://doi.org/10.1208/s12248-020-00465-w
- Ohe M, Shida H, Jodo S et al (2020) Macrolide treatment for COVID-19: Will this be the way forward? Biosci Trends 14, 159-160 https://doi.org/10.5582/bst.2020.03058
- Chorin E, Dai M, Shulman E et al (2020) The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Nat Med 26, 808-809 https://doi.org/10.1038/s41591-020-0888-2
- Ramireddy A, Chugh H, Reinier K et al (2020) Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring. J Am Heart Assoc 9, e017144
- Juurlink DN (2014) The cardiovascular safety of azithromycin. CMAJ 186, 1127-1128 https://doi.org/10.1503/cmaj.140572
- Mitra RL, Greenstein SA and Epstein LM (2020) An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine. Heart Rhythm Case Rep 6, 244-248
- Ray WA, Murray KT, Hall K, Arbogast PG and Stein CM (2012) Azithromycin and the risk of cardiovascular death. N Engl J Med 366, 1881-1890 https://doi.org/10.1056/NEJMoa1003833
- Juurlink DN (2020) Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. CMAJ 192, E450-E453 https://doi.org/10.1503/cmaj.200528
- Gintant G, Sager PT and Stockbridge N (2016) Evolution of strategies to improve preclinical cardiac safety testing. Nat Rev Drug Discov 15, 457-471 https://doi.org/10.1038/nrd.2015.34
- Satsuka A and Kanda Y (2020) Cardiotoxicity Assessment of Drugs Using Human iPS Cell-Derived Cardiomyocytes: Toward Proarrhythmic Risk and Cardio-Oncology. Curr Pharm Biotechnol 21, 765-772 https://doi.org/10.2174/1389201020666190628143345
- Sharma A, McKeithan WL, Serrano R et al (2018) Use of human induced pluripotent stem cell-derived cardiomyocytes to assess drug cardiotoxicity. Nat Protoc 13, 3018-3041 https://doi.org/10.1038/s41596-018-0076-8
- Thomson JA, Itskovitz-Eldor J, Shapiro SS et al (1998) Embryonic stem cell lines derived from human blastocysts. Science 282, 1145-1147 https://doi.org/10.1126/science.282.5391.1145
- Cheng DK, Tung L and Sobie EA (1999) Nonuniform responses of transmembrane potential during electric field stimulation of single cardiac cells. Am J Physiol 277, H351-362
- Rast G, Weber J, Disch C, Schuck E, Ittrich C and Guth BD (2015) An integrated platform for simultaneous multiwell field potential recording and Fura-2-based calcium transient ratiometry in human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes. J Pharmacol Toxicol Methods 75, 91-100 https://doi.org/10.1016/j.vascn.2015.04.005
- Inciardi RM, Lupi L, Zaccone G et al (2020) Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 5, 819-824 https://doi.org/10.1001/jamacardio.2020.1096
- Sala S, Peretto G, Gramegna M et al (2020) Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. Eur Heart J 41, 1861-1862 https://doi.org/10.1093/eurheartj/ehaa286
- Tavazzi G, Pellegrini C, Maurelli M et al (2020) Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail 22, 911-915 https://doi.org/10.1002/ejhf.1828
- Sirenko O, Crittenden C, Callamaras N et al (2013) Multiparameter in vitro assessment of compound effects on cardiomyocyte physiology using iPSC cells. J Biomol Screen 18, 39-53 https://doi.org/10.1177/1087057112457590
- Traebert M, Dumotier B, Meister L, Hoffmann P, Dominguez-Estevez M and Suter W (2004) Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells. Eur J Pharmacol 484, 41-48 https://doi.org/10.1016/j.ejphar.2003.11.003
- Mubagwa K (2020) Cardiac effects and toxicity of chloroquine: a short update. Int J Antimicrob Agents 56, 106057 https://doi.org/10.1016/j.ijantimicag.2020.106057
- Vicente J, Zusterzeel R, Johannesen L et al (2019) Assessment of Multi-Ion Channel Block in a Phase I Randomized Study Design: Results of the CiPA Phase I ECG Biomarker Validation Study. Clin Pharmacol Ther 105, 943-953 https://doi.org/10.1002/cpt.1303
- Haeusler IL, Chan XHS, Guerin PJ and White NJ (2018) The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review. BMC Med 16, 200 https://doi.org/10.1186/s12916-018-1188-2
- Lian X, Zhang J, Azarin SM et al (2013) Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/beta-catenin signaling under fully defined conditions. Nat Protoc 8, 162-175 https://doi.org/10.1038/nprot.2012.150
- Lian X, Hsiao C, Wilson G et al (2012) Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci U S A 109, E1848-1857 https://doi.org/10.1073/pnas.1200250109
- Tohyama S, Hattori F, Sano M et al (2013) Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell 12, 127-137 https://doi.org/10.1016/j.stem.2012.09.013